
Software developer RadLogics has reached an agreement to be acquired by a pair of investment firms from Asia.
East Ocean Ventures of Singapore and Tianjin Dazhen Asset Management of Tianjin, China, have agreed to acquire 100% of RadLogics. The deal is expected to close in the third quarter of the 2018 calendar year and is subject to customary regulatory approvals and closing conditions.
RadLogics received U.S. Food and Drug Administration (FDA) clearance for its flagship product, AlphaPoint, in 2012. Now called Virtual Resident, the software uses machine learning to assist radiologists in interpreting CT, MR, and x-ray images.
The firms plan to accelerate R&D of the Virtual Resident platform, as well as to ramp up its sales and distribution in both the U.S. and Asia, according to Moshe Becker, CEO of the company.
"These two funds have substantial footprints among healthcare providers and distributors in Asia," Becker told AuntMinnie.com. "They see a huge opportunity to take our technology and the validation that we have accomplished in the U.S. and leverage that to provide the same kind of solutions in Asia on a much larger scale than what we have done so far."
RadLogics will retain its existing management team and create a new business unit in Asia, Becker said.
The company has also resolved an issue with the FDA in which the agency sent the company a warning letter over content used to describe its products, which was subsequently updated.















![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)



